BACKGROUND: HPV16 variants are associated with different risks for development of CIN3 and invasive cancer, although all are carcinogenic. The relationship of HPV 16 variants to cancer survival has not been studied. METHODS: 155 HPV16-positive cervical cancers were categorized according to European and non-European variant patterns by DNA sequencing of the E6 open reading frame. Clinico-pathologic parameters and clinical outcome were collected by chart review and death registry data. RESULTS: Of the 155 women (mean age 44.7 years; median follow-up 26.7 months), 85.2% harbored European variants while 14.8% had non-European sequences. HPV16 variants differed by histologic cell type (p = 0.03) and stage (1 vs. 2+; p = 0.03). Overall, 107 women (68.0%) were alive with no evidence of cancer, 42 (27.1%) died from cervical cancer, 2 (1.3%) were alive with cervical cancer, and 4 (2.6%) died of other causes. Death due to cervical cancer was associated with European variant status (p < 0.01). While 31% of women harboring tumors with European variants died from cervical cancer during follow-up, only 1 of 23 (4.4%) non-European cases died of cancer. The better survival for non-European cases was partly mediated by lower stage at diagnosis. CONCLUSIONS: Overall, invasive cervical cancers with non-European variants showed a less aggressive behavior than those with European variants. These findings should be replicated in a population with more non-European cases.
BACKGROUND: HPV16 variants are associated with different risks for development of CIN3 and invasive cancer, although all are carcinogenic. The relationship of HPV 16 variants to cancer survival has not been studied. METHODS: 155 HPV16-positive cervical cancers were categorized according to European and non-European variant patterns by DNA sequencing of the E6 open reading frame. Clinico-pathologic parameters and clinical outcome were collected by chart review and death registry data. RESULTS: Of the 155 women (mean age 44.7 years; median follow-up 26.7 months), 85.2% harbored European variants while 14.8% had non-European sequences. HPV16 variants differed by histologic cell type (p = 0.03) and stage (1 vs. 2+; p = 0.03). Overall, 107 women (68.0%) were alive with no evidence of cancer, 42 (27.1%) died from cervical cancer, 2 (1.3%) were alive with cervical cancer, and 4 (2.6%) died of other causes. Death due to cervical cancer was associated with European variant status (p < 0.01). While 31% of women harboring tumors with European variants died from cervical cancer during follow-up, only 1 of 23 (4.4%) non-European cases died of cancer. The better survival for non-European cases was partly mediated by lower stage at diagnosis. CONCLUSIONS: Overall, invasive cervical cancers with non-European variants showed a less aggressive behavior than those with European variants. These findings should be replicated in a population with more non-European cases.
Authors: Ni Li; Silvia Franceschi; Rebecca Howell-Jones; Peter J F Snijders; Gary M Clifford Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396
Authors: Rosemary E Zuna; William E Moore; Rebecca P Shanesmith; S Terence Dunn; Sophia S Wang; Mark Schiffman; Gregory L Blakey; Travis Teel Journal: Int J Cancer Date: 2009-12-01 Impact factor: 7.396
Authors: Mark Schiffman; Ana Cecilia Rodriguez; Zigui Chen; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Rob Desalle; Brian Befano; Kai Yu; Mahboobeh Safaeian; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Martha Hutchinson; Diane Solomon; Philip E Castle; Robert D Burk Journal: Cancer Res Date: 2010-03-30 Impact factor: 12.701
Authors: J Berumen; R M Ordoñez; E Lazcano; J Salmeron; S C Galvan; R A Estrada; E Yunes; A Garcia-Carranca; G Gonzalez-Lira; A Madrigal-de la Campa Journal: J Natl Cancer Inst Date: 2001-09-05 Impact factor: 13.506
Authors: Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen Journal: Virology Date: 2004-06-20 Impact factor: 3.616
Authors: Sophia S Wang; Rosemary E Zuna; Nicolas Wentzensen; S Terence Dunn; Mark E Sherman; Michael A Gold; Mark Schiffman; Sholom Wacholder; Richard A Allen; Ingrid Block; Kim Downing; Jose Jeronimo; J Daniel Carreon; Mahboobeh Safaeian; David Brown; Joan L Walker Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister Journal: Int J Cancer Date: 2019-01-04 Impact factor: 7.396
Authors: Rodrigo Lopes da Silva; Zulmira da Silva Batista; Gerusinete Rodrigues Bastos; Ana Paula Almeida Cunha; Fábio Vidal Figueiredo; Lailson Oliveira de Castro; Liwerbeth Dos Anjos Pereira; Marcos Antonio Custódio Neto da Silva; Flávia Castello Branco Vidal; Maria Claudene Barros; Elmary da Costa Fraga; Luciane Maria Oliveira Brito; Maria do Carmo Lacerda Barbosa; Miguel Ângelo Martins Moreira; Maria do Desterro Soares Brandão Nascimento Journal: BMC Womens Health Date: 2020-08-01 Impact factor: 2.809
Authors: Eduardo L Franco; Silvia de Sanjosé; Thomas R Broker; Margaret A Stanley; Myriam Chevarie-Davis; Sandra D Isidean; Mark Schiffman Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Ana Pavla Almeida Diniz Gurgel; Bárbara Simas Chagas; Carolina Medeiros do Amaral; Kamylla Conceição Gomes Nascimento; Lígia Rosa Sales Leal; Jacinto da Costa Silva Neto; Maria Tereza Cartaxo Muniz; Antonio Carlos de Freitas Journal: Biomed Res Int Date: 2015-02-22 Impact factor: 3.411
Authors: Bárbara Simas Chagas; Manola Comar; Ana Pavla Almeida Diniz Gurgel; Sérgio Paiva; Silva Seraceni; Antonio Carlos de Freitas; Sergio Crovella Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: Daan T Geraets; Leen-Jan van Doorn; Bernhard Kleter; Brigitte Colau; Diane M Harper; Wim G V Quint Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240